Trial Profile
Use of sorafenib in recurrent hepatocellular carcinoma (HCC) after liver transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium
- 11 Aug 2015 New trial record